Evidence map›Paper›PMID 35386613›Full record

Trial reportClinical ophthalmology (Auckland, N.Z.)2022

Performance of a Translucent Activator for LipiFlow Vectored Thermal Pulse (VTP) Treatment of Meibomian Gland Dysfunction.

Jerry G Hu, Vin T Dang, Daniel H Chang, Damien F Goldberg, Cheryl McKinnon, Katherine Makedonsky, Michal Laron, Leilei Ji

Open access · goldAbstract readCase ReportsClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical ophthalmology (Auckland, N.Z.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jerry G HuTexas Eye & Laser Center, P.A., Hurst, TX, USA.
Vin T DangEmpire Eye and Laser Center, Bakersfield, CA, USA.
Daniel H ChangEmpire Eye and Laser Center, Bakersfield, CA, USA.ORCID 0000-0001-6307-6342
Damien F GoldbergWolstan & Goldberg Eye Associates, Torrance, CA, USA.
Cheryl McKinnonJohnson & Johnson Surgical Vision, Inc., Milpitas, CA, USA.ORCID 0000-0003-2430-3498
Katherine MakedonskyJohnson & Johnson Surgical Vision, Inc., Milpitas, CA, USA.
Michal LaronJohnson & Johnson Surgical Vision, Inc., Milpitas, CA, USA.ORCID 0000-0002-3097-7272
Leilei JiJohnson & Johnson Surgical Vision, Inc., Irvine, CA, USA.
Johnson & Johnson (United States) · USEmpire Eye Physicians · USWolstan & Goldberg Eye Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Investigator feedback was used to assess the clinical use of the LipiFlow Patients and Methods: This was a prospective, open-label clinical investigation. A total of 88 eyes (44 subjects) were treated using the LipiFlow Results: The new translucent Activator provided successful LipiFlow Conclusion: The overall investigators' impressions on usage and functionality of LipiFlow

Indexed as

Activator ClearLipiFlow® vectored thermal pulsation

Identifiers

PMID35386613
PMCPMC8977218
OpenAlexW4226071088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.